Full Press Release Details
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration.
BIIB
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Key Takeaway: Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration